Objective: This study aims to investigate the clinical value of reduning injection in treating acute upper respiratory infection.
Methods: A total of 72 patients with acute upper respiratory infection in our hospital from March 2015 to February 2017 were selected and divided into the control and observation groups randomly by the odd-even method. The control group (36 cases) was treated by ribavirin injection, whereas the observation group (36 cases) was treated by reduning injection. The effect of clinical therapies, improvement of symptoms, normal proportions of White Blood Cells (WBCs) and neutrophils, and statistical results of occurrence rate of untoward effect between the two groups were compared.
Results: The observation group presents significantly higher therapeutic effect (97.22%) than that in the control group (58.33%) (P<0.05). The improvement time of symptoms in the observation group is shortened significantly compared with that in the control group (P<0.05). The observation group shows dramatically higher proportions of WBCs and neutrophils than those in the control group (P<0.05). The occurrence rate of untoward effect in the observation group is 2.78%, which is reduced dramatically compared with that in the control group (22.22%) (P<0.05).
Conclusions: Reasonable reduning injection in clinical treatment of acute upper respiratory infection can guarantee improvement in therapeutic effect, shortening in improvement time of symptoms, growth in proportions of WBCs and neutrophils, and reduction in untoward effect. This approach can optimize prognosis of patients with acute upper respiratory infection.